Nocardiosis: A Comprehensive Disease Characteristics Report

Disease: Nocardiosis · MONDO: MONDO:0017776 · Category: Infectious Disease Report type: Disease knowledge-base template (15 sections) · Iterations completed: 5 · Findings confirmed: 8 · Papers reviewed: 59 Evidence base: Literature synthesis (PubMed). No patient-level data files were provided; all content is derived from aggregated disease-level literature (systematic reviews, multicenter cohorts, case series), not individual EHR data.

Summary

Nocardiosis is an opportunistic bacterial infection caused by aerobic, Gram-positive, weakly (partially) acid-fast, branching filamentous actinomycetes of the genus Nocardia. It is an environmentally acquired, non-heritable infectious disease: the organism lives in soil, decaying vegetation and water, and enters the host by inhalation (producing pulmonary disease, the primary presentation) or by traumatic inoculation (producing cutaneous/subcutaneous disease, including actinomycetoma). Its defining clinical feature is a strong propensity for hematogenous dissemination to the central nervous system, where it forms ring-enhancing brain abscesses carrying a case-fatality of roughly 20–30%. Because the etiology is infectious rather than genetic, the many template sections that assume a Mendelian/heritable disease (causal human genes, inheritance pattern, penetrance, germline variant classification, genetic screening) are Not Applicable; the molecular characterization instead centers on pathogen virulence factors and antimicrobial-resistance determinants.

The disease disproportionately afflicts hosts with impaired cell-mediated immunity. The dominant risk factors — corticosteroid therapy, solid-organ and hematopoietic-cell transplantation, high calcineurin-inhibitor (tacrolimus) exposure, low CD4 counts (HIV/AIDS), and anti–GM-CSF autoantibodies — all converge on defective T-cell/macrophage killing. In solid-organ transplant recipients nocardiosis affects 0.04–3.5% of patients and confers a roughly 10-fold higher one-year mortality than in transplant recipients without infection. Diagnosis rests on demonstrating branching, beaded, weakly acid-fast filaments on microscopy, growth on culture (slow, days to weeks), and species-level identification by MALDI-TOF MS, 16S rRNA gene sequencing, MLSA, or whole-genome/metagenomic sequencing. Chest CT typically shows nodules/masses, consolidation and cavitation; brain MRI shows ring-enhancing abscesses with vasogenic edema.

Treatment is prolonged (months) and species- and susceptibility-guided. Linezolid is universally active against Nocardia; trimethoprim-sulfamethoxazole (TMP-SMX) and amikacin cover >90% of isolates and form the backbone of therapy, with carbapenems and third-generation cephalosporins used for severe/disseminated disease and neurosurgical drainage for brain abscesses. Resistance is species-specific and gene-encoded (e.g., blaFAR-1 in N. farcinica, blaAST-1 in N. cyriacigeorgica, gyrA mutations, 16S rRNA methyltransferases). Prevention is chiefly dose-dependent TMP-SMX chemoprophylaxis in high-risk immunosuppressed patients plus minimization of net immunosuppression; no vaccine exists for humans.

Section 1 — Disease Information

Overview. Nocardiosis is a localized or disseminated opportunistic infection caused by Nocardia spp., environmental actinomycetes. It most often begins as a subacute-to-chronic pulmonary infection and can spread hematogenously, with the CNS the most common secondary site, followed by skin/soft tissue. It is not contagious person-to-person.

Key identifiers. - MONDO: MONDO:0017776 (nocardiosis) - ICD-10: A43 (A43.0 pulmonary, A43.1 cutaneous, A43.8 other forms, A43.9 unspecified); ICD-11: 1C1F - MeSH: D009617 (Nocardia Infections) - OMIM / Orphanet: Not a Mendelian disorder — no OMIM disease number. Orphanet lists nocardiosis as a rare infectious disease. - Causative genus (NCBI Taxonomy): Nocardia (taxid 1817); key species include N. asteroides, N. farcinica, N. cyriacigeorgica, N. brasiliensis, N. otitidiscaviarum, N. nova, N. seriolae (fish).

Synonyms / alternative names. Nocardia infection; nocardial infection; actinomycetoma / Nocardial mycetoma (for the chronic subcutaneous form). Historically many cases were attributed to "N. asteroides complex" before molecular taxonomy split it into distinct species.

Information source. The evidence base is a mix of individual patient reports/case series (EHR-derived clinical cohorts) and aggregated disease-level resources (systematic reviews, multicenter case-control studies). No population-level germline registry applies.

Section 2 — Etiology

Primary cause — infectious. Nocardiosis is caused by infection with Nocardia spp. As one review states, "Nocardia are uncommon pathogens that disproportionately afflict the immunocompromised host" (PMID: 29668123). Acquisition is by inhalation of soil dust (pulmonary/disseminated disease) or by percutaneous trauma with soil/plant contamination (cutaneous disease, actinomycetoma).

Risk factors (host, non-genetic). Impaired cell-mediated immunity is the central predisposing state: - Corticosteroid therapy — the single most common predisposing factor; in a systematic review of CNS nocardiosis, corticosteroid use was present in 55.8% of patients (PMID: 35700710). - Solid-organ transplantation (SOT) — affects 0.04–3.5% of recipients; independent risk factors include high calcineurin-inhibitor trough levels (OR 6.11, 95% CI 2.58–14.51), tacrolimus use (OR 2.65, 95% CI 1.17–6.00) and corticosteroid dose (OR 1.12 per unit, 95% CI 1.03–1.22) (PMID: 27090987). - Hematopoietic-cell transplantation (HCT) and delayed CD4 T-cell recovery. - High-dose methylprednisolone and CMV infection (independent risk factors in renal transplant recipients; PMID: 39254072). - HIV/AIDS with low CD4 counts. - Anti–GM-CSF autoantibodies / autoimmune pulmonary alveolar proteinosis (French multicenter study, 38915339). - Chronic lung disease (bronchiectasis, COPD), diabetes mellitus, connective tissue disease, malignancy. - Sulfonamide allergy label — associated with higher nocardiosis risk in SOT (HR 3.85, 95% CI 1.44–10.30), likely via avoidance of protective TMP-SMX prophylaxis (PMID: 39136148).

Genetic risk factors (human host). No established Mendelian susceptibility gene. Rare monogenic immunodeficiencies affecting phagocyte/T-cell function (e.g., chronic granulomatous disease) can predispose to Nocardia, but there is no disease-causing germline locus. Anti–GM-CSF autoantibody-driven susceptibility is acquired, not inherited. This subsection is largely Not Applicable.

Protective factors. TMP-SMX chemoprophylaxis reduces risk in a dose-dependent manner (see Section 13). No genetic protective variant is defined.

Gene–environment interactions. Not applicable in the human host in a Mendelian sense. The relevant interaction is iatrogenic immunosuppression × environmental exposure (soil/dust) — pharmacologic suppression of cell-mediated immunity converts an environmental saprophyte into a lethal pathogen.

Section 3 — Phenotypes

Phenotypes are infection manifestations, not heritable traits. HPO terms below are suggested for knowledge-base mapping.

• Age of onset: Predominantly adults; mean age ~55 ± 16 y in CNS series (PMID: 35700710). Not congenital.
• Severity: Variable — from indolent cutaneous lesions to fatal disseminated/CNS disease.
• Progression: Subacute to chronic; can be rapidly progressive in severely immunosuppressed hosts.
• Quality-of-life impact: Substantial in disseminated/CNS disease (neurological sequelae, prolonged multi-month therapy, hospitalization); disease-specific QoL instruments are not established.

Section 4 — Genetic / Molecular Information

Human causal genes: Not Applicable. Nocardiosis is infectious; there is no human causal gene, pathogenic germline variant, ACMG/AMP variant classification, modifier gene, inheritance-linked epigenetic lesion, or chromosomal abnormality. Sections requiring gnomAD allele frequency, somatic vs germline origin, and human variant nomenclature do not apply.

Molecular characterization instead centers on the pathogen genome. Nocardia virulence and resistance are gene-encoded (detailed in Sections 5, 6, 12). Genomic analysis of N. seriolae and clinical isolates identified virulence-associated genes including sodA (superoxide dismutase), katG (catalase), and mycolic-acid/cell-wall biosynthesis genes (pks13, fadD32, pcaA, mftF) (PMID: 40827537). Resistance determinants include blaFAR-1, blaAST-1, aph(2″), gyrA Ser83Ala, and a 16S rRNA m1A1408 methyltransferase (PMID: 37527397).

Section 5 — Environmental Information

Environmental reservoir. Nocardia is a ubiquitous soil saprophyte found in soil, decaying organic/plant matter, dust and water. Exposure to soil and dust (gardening, agriculture, construction) is the principal environmental risk; several case reports link disease to occupational/recreational soil exposure.

Lifestyle factors. Smoking and chronic lung disease increase pulmonary susceptibility; alcohol use and diabetes are frequent comorbidities. These are host-modifying rather than direct causal factors.

Infectious agents (the cause). Human disease is caused by multiple Nocardia species. Predominant clinical isolates include N. asteroides, N. farcinica, and N. cyriacigeorgica (PMID: 41319540); N. brasiliensis is the classic cause of actinomycetoma; N. otitidiscaviarum shows unpredictable susceptibility; N. seriolae causes fish nocardiosis. N. farcinica is characteristically multidrug-resistant and over-represented in brain/disseminated disease.

Section 6 — Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Environmental exposure — the host inhales soil/dust aerosols containing Nocardia, or the organism is inoculated through broken skin (trauma). → leads to
2. Deposition in alveoli (or dermis) and encounter with resident macrophages. → leads to
3. Phagocytosis by macrophages, which would normally kill the organism. → but
4. Immune-evasion branch: Nocardia resists intracellular killing. Secreted catalase (katG) and superoxide dismutase (sodA) detoxify reactive oxygen species; the mycolic-acid–rich cell wall (built by pks13, fadD32, pcaA, mftF) resists phagolysosomal degradation; secreted proteases damage tissue and immunosuppressive metabolites (e.g., brasilicardin A) blunt local immunity (PMID: 40827537; PMID: 33956121). → results in
5. Intracellular survival and replication within macrophages — favored when host cell-mediated immunity is impaired (corticosteroids, calcineurin inhibitors, low CD4). → leads to
6. Local suppurative/granulomatous inflammation. In the lung: pneumonia, nodules, consolidation and cavitation. A local anti-inflammatory (immunosuppressive) microenvironment coexists with a systemic acquired immune response (PMID: 22825801). Nitric oxide (eNOS) is required for actinomycetoma lesion formation in mice (PMID: 33956121). → then branches 7a. Containment branch (competent immunity): granuloma / macrophage barrier walls off the organism → localized, indolent disease. 7b. Dissemination branch (impaired immunity): organisms breach the local barrier and enter the bloodstream. → leads to
7. Hematogenous spread to the CNS (most common secondary site), skin/soft tissue, and other organs. → results in
8. Ring-enhancing brain abscess with surrounding vasogenic edema. → leads to
9. Clinical manifestation: focal neurological deficit, altered mental status, seizures; untreated or delayed, death (CNS case-fatality ~23%).

(Steps 4–5 are supported by pathogen genomics and animal models; the human host-side detail is inferred from clinical association with cell-mediated immune defects rather than mechanistically demonstrated in humans.)

Detail by category

• Molecular pathways / cellular processes: Macrophage phagocytosis and oxidative burst; ROS detoxification; granuloma formation; chronic inflammation. Suggested GO terms: GO:0006909 (phagocytosis), GO:0000302 (response to reactive oxygen species), GO:0006954 (inflammatory response), GO:0006801 (superoxide metabolic process).
• Protein dysfunction (pathogen): Mycolic-acid synthesis enzymes and antioxidant enzymes are gain-of-function virulence assets, not host defects.
• Immune involvement: Host defect is impaired cell-mediated immunity (T-cell/macrophage axis); IFN-γ–driven macrophage activation is protective (demonstrated in fish models, PMID: 33045332).
• Tissue damage mechanisms: Suppuration/necrosis (abscess), protease-mediated tissue destruction, granulomatous fibrosis.
• Cell types (CL terms): macrophage (CL:0000235), neutrophil (CL:0000775), T cell (CL:0000084), CD4+ T cell (CL:0000624).

Section 7 — Anatomical Structures Affected

• Primary organ: Lung (UBERON:0002048) — the portal of entry for inhaled disease; pulmonary infection in ~64% of cases.
• Most common secondary organ: Brain (UBERON:0000955) — brain abscess in the vast majority of CNS cases.
• Other sites: skin/subcutaneous tissue (UBERON:0002097), bone/joint/bursa, pericardium, lymph nodes, bloodstream (bacteremia), eye, kidney.
• Body systems: respiratory, nervous (CNS), integumentary, and (when disseminated) systemic/cardiovascular.
• Tissue level: lung parenchyma (alveolar epithelium and interstitium), brain parenchyma, dermis/subcutis.
• Cell populations (CL): macrophage (CL:0000235), neutrophil (CL:0000775).
• Subcellular (GO cellular component): phagosome/phagolysosome (GO:0045335 / GO:0032010) is the key intracellular niche.
• Localization/lateralization: Pulmonary lesions often multifocal/bilateral; brain abscesses may be single or multiple, unilateral or bilateral.

Section 8 — Temporal Development

• Onset: Predominantly adult; subacute to chronic (insidious) course. In SOT, median onset is 17.5 months post-transplant (PMID: 27090987). Acute fulminant presentations occur in severe immunosuppression.
• Progression: From localized pulmonary focus to disseminated/CNS disease over weeks to months if untreated. Cavitation is more frequent in immunosuppressed and disseminated disease.
• Course pattern: Progressive without treatment; treatment-responsive but requires prolonged (weeks to ≥6–12 months) therapy to prevent relapse.
• Duration: Not self-limited; chronic if untreated.
• Critical period: Early diagnosis and drainage are decisive — delay increases CNS/dissemination and mortality. Prophylaxis interruption during immunosuppression transitions is a recognized trigger.

Section 9 — Inheritance and Population

• Inheritance: Not Applicable — infectious, non-heritable. No inheritance pattern, penetrance, expressivity, anticipation, mosaicism, founder effect, consanguinity role, or carrier frequency.
• Epidemiology: Estimated incidence historically ~500–1,000 US cases/year (increasing with immunosuppressed populations); precise population incidence is uncertain and under-reported. In SOT, cumulative incidence 0.04–3.5% (PMID: 27090987).
• Demographics: Male predominance (~70.8% male in CNS series); mean age ~55 y (PMID: 35700710). Notably, ~34% of CNS cases were immunocompetent, so immunocompetence does not exclude the diagnosis.
• Geographic distribution: Worldwide; actinomycetoma (N. brasiliensis) is more common in tropical/subtropical regions. Species distribution varies by region (e.g., N. cyriacigeorgica common in India, PMID: 40112638).

Section 10 — Diagnostics

Microbiology (gold standard). Direct microscopy of Gram-stained smears shows branching, beaded, filamentous Gram-positive rods that are weakly/partially acid-fast on modified Kinyoun stain. Gram-stained smears are emphasized as a valuable, easily-overlooked diagnostic step (PMID: 36636850). Culture is slow (days to weeks). Species identification uses MALDI-TOF MS, 16S rRNA gene sequencing, MLSA, WGS, and metagenomic next-generation sequencing (mNGS) (PMID: 42258415).

Imaging. - Chest CT: Multiple/solitary nodules or masses are the most common finding (94.12% in one series), with ground-glass opacities (76.47%), patchy consolidation (73.53%), and cavitation (52.94%) (PMID: 37185005). Cavitation is significantly more frequent in immunosuppressed than immunocompetent patients (85% vs 29%, p = 0.005, PMID: 37185005) and in disseminated vs localized disease (64.3% vs 32.8%, PMID: 38529577). - Brain MRI/CT (contrast): ring-enhancing abscess(es) with vasogenic edema.

Susceptibility testing. Broth microdilution (CLSI) for TMP-SMX, linezolid, amikacin, carbapenems, third-generation cephalosporins, amoxicillin-clavulanate, moxifloxacin, minocycline. Species identification predicts likely resistance patterns.

Clinical criteria / differential diagnosis. No formal scoring system; diagnosis is microbiological. Differential includes tuberculosis, actinomycosis, fungal infection (aspergillosis, cryptococcosis), metastatic malignancy and lung cancer — pulmonary and CNS nocardiosis frequently mimic malignancy (PMID: 42007821).

Screening / genetic testing: Not applicable (no germline component).

Section 11 — Outcome / Prognosis

• CNS nocardiosis case-fatality: 22.8% overall (PMID: 35700710); nocardial brain abscesses carry a 20–55% mortality (PMID: 39780099).
• SOT nocardiosis: one-year all-cause mortality 16.2% vs 1.3% in matched controls — a 10-fold increase (PMID: 28329348); 12-month mortality ~16.8% in a multicenter SOT cohort, with liver transplantation and shorter symptom-to-presentation time independently associated with death (PMID: 36303280).
• Prognostic factors: immunosuppression intensity, CNS/disseminated involvement, species (N. farcinica worse), delayed diagnosis. Surgery improves survival in CNS disease (multivariate OR 2.4, 95% CI 0.99–4.11, p = 0.046, PMID: 35700710).
• Complications: brain abscess rupture, respiratory failure, multi-organ dissemination, relapse if therapy is too short.
• Recovery: Good with early, susceptibility-guided, adequately prolonged therapy plus drainage; poor when diagnosis is delayed.

Section 12 — Treatment

Backbone pharmacotherapy. Nocardia susceptibility is favorable to a defined set of agents:

Data: Israeli WGS study of 138 strains — "Linezolid was active against all isolates, followed by trimethoprim/sulfamethoxazole (93%) and amikacin (91%)" (PMID: 37527397); Indian series — "All tested isolates were susceptible to linezolid and 96% susceptible to amikacin" (PMID: 40112638).

Species-specific resistance (gene-encoded): blaFAR-1 → ceftriaxone resistance in N. farcinica; blaAST-1 → amoxicillin-clavulanate resistance in N. cyriacigeorgica/N. neocaledoniensis; aph(2″) → tobramycin resistance; gyrA Ser83Ala → ciprofloxacin resistance; 16S rRNA m1A1408 methyltransferase → amikacin resistance (PMID: 37527397).

Treatment strategy. - Localized pulmonary/cutaneous: TMP-SMX (monotherapy can be effective in SOT — favorable outcome in 19/24 patients completing ≥30 days, PMID: 34143917). - Severe/disseminated/CNS: combination therapy (e.g., TMP-SMX + linezolid ± amikacin/carbapenem), often 2–3 drugs initially, then oral step-down; total duration typically 6–12 months (longer in CNS/immunosuppressed). - Surgical drainage of brain and large soft-tissue abscesses improves outcomes. - Personalized approach: therapy is species/susceptibility-guided via molecular ID and antimicrobial susceptibility testing. - Pharmacogenomics: relevant to the sulfonamide component (sulfa hypersensitivity) but no Nocardia-specific PGx.

Section 13 — Prevention

• Primary prevention: TMP-SMX chemoprophylaxis in high-risk immunosuppressed patients. An individual-patient-data meta-analysis of SOT recipients is titled "Trimethoprim-sulfamethoxazole significantly reduces the risk of nocardiosis in solid organ transplant recipients" and assessed "its dose-response relationship, its effect on preventing disseminated nocardiosis, and the risk of TMP-SMX resistance in case of breakthrough infection" (PMID: 37865337). Protection is dose-dependent: low-dose (thrice-weekly, PJP-dosing) cotrimoxazole "was not found to prevent nocardiosis" (PMID: 27090987), whereas higher/daily dosing is protective.
• Breakthrough infections occur despite prophylaxis and in-vitro susceptibility (PMID: 42135975), reflecting host-immunity and drug-exposure factors; prophylaxis rarely selects resistance (PMID: 29668123).
• Minimize net immunosuppression where clinically feasible.
• Environmental/occupational caution: reduce soil/dust exposure in severely immunosuppressed patients (gloves, masks for gardening).
• De-labeling sulfa allergy before transplant to preserve access to protective prophylaxis (PMID: 39136148).
• Immunization: No human vaccine exists.

Section 14 — Other Species / Natural Disease

• Taxonomy of affected hosts: Humans (Homo sapiens, NCBI:9606) and many animals. Nocardia is a natural pathogen of fish (N. seriolae), dogs, cattle, and other mammals (PMID: 4604823).
• Fish nocardiosis: N. seriolae causes chronic granulomatous disease in >40 species of cultured marine/freshwater fish (largemouth bass, snakehead, amberjack, channel catfish), causing major aquaculture losses (PMID: 38641217; PMID: 40827537).
• Comparative pathology: Granuloma formation is conserved across teleosts and mammals; teleost granulomas form a macrophage "barrier" via an epithelialization program (PMID: 41443521).
• Zoonotic potential: Low/negligible for direct animal-to-human transmission; humans and animals are independently infected from the shared environmental soil/water reservoir.

Section 15 — Model Organisms

• Murine models: The C57BL/6 footpad actinomycetoma model (N. brasiliensis) reproduces chronic granulomatous lesions; eNOS-knockout mice are protected from actinomycetoma, with increased T-cell proliferation and lower TNF-α — establishing that nitric oxide is required for lesion development (PMID: 33956121).
• Fish models: Largemouth bass, snakehead (Channa argus), amberjack, and channel catfish infected with N. seriolae recapitulate chronic granulomatous disease and macrophage barrier biology; used to study pathogenesis, immune response (IFN-γ), and vaccine/adjuvant development (PMID: 38641217; PMID: 41443521; PMID: 33045332; PMID: 29665356).
• Phenotype recapitulation: Both systems reproduce granuloma formation, macrophage-centered immunity, and chronicity. Limitations: rodent/fish models do not fully mirror the human iatrogenic-immunosuppression context (transplant, corticosteroids) or human CNS abscess dissemination.

Key Findings (with expanded evidence)

Finding 1 — Opportunistic infection: lung primary, CNS most common secondary site

In a retrospective series of 44 nocardiosis cases, pulmonary infection occurred in 28/44 (64%), disseminated disease in 13/44 (30%), and extrapulmonary single-organ disease in 3/44; 40/44 had comorbidities and 13/44 were on long-term glucocorticoids/immunosuppressants (PMID: 41319540). Predominant isolates were N. asteroides, N. farcinica, and N. cyriacigeorgica. The opportunistic nature is captured succinctly: "Nocardia are uncommon pathogens that disproportionately afflict the immunocompromised host" (PMID: 29668123).

Finding 2 — CNS nocardiosis: ~23% case-fatality; N. farcinica predominates; surgery improves survival

A systematic review of adult CNS nocardiosis (129 papers) found mean age 55 ± 16 y, 70.8% male, N. farcinica the commonest species (39.6%), corticosteroid use the most common predisposing factor (55.8%), brain abscess in 86.9%, and overall case-fatality 22.8%; surgery independently improved survival (OR 2.4, 95% CI 0.99–4.11, p = 0.046) (PMID: 35700710). Nocardial brain abscesses account for ~2% of all brain abscesses but carry 20–55% mortality (PMID: 39780099).

Finding 3 — Corticosteroids, transplantation and cell-mediated immune defects dominate risk

In renal transplant recipients, "High-dose methylprednisolone and cytomegalovirus infection were independent risk factors for Nocardia infection" (PMID: 39254072). TMP-SMX prophylaxis provides imperfect protection but does not select resistance: "The use of TMP-SMX prophylaxis was not associated with TMP-SMX-resistant Nocardia" (PMID: 29668123).

Finding 4 — Nocardiosis affects 0.04–3.5% of SOT recipients; immunosuppression intensity is the driver

The European multicenter case-control study (117 cases/234 controls) identified "high calcineurin inhibitor trough levels in the month before diagnosis (odds ratio [OR], 6.11; 95% confidence interval [CI], 2.58-14.51), use of tacrolimus (OR, 2.65; 95% CI, 1.17-6.00) and corticosteroid dose (OR, 1.12; 95% CI, 1.03-1.22)" as independent risk factors, and found "low-dose cotrimoxazole prophylaxis was not found to prevent nocardiosis" (PMID: 27090987). One-year mortality was "10-fold higher in SOT patients with nocardiosis than in those without" (PMID: 28329348).

Finding 5 — Virulence: ROS-detoxifying enzymes, mycolic-acid wall, proteases, immunosuppressive metabolites

Genomics identified "espG, mftF, pcaA, fadD32, pks13, narJ, feoB, sodA, katG and mceF" virulence-associated genes (PMID: 40827537). N. brasiliensis "produces proteases that may play a role in tissue damage, as well as immunosuppressive molecules, such as brasilicardin A", and nitric oxide is required for lesions: "Inflammation and actinomycetoma were prevented in genetically modified [eNOS-knockout] mice infected with N. brasiliensis" (PMID: 33956121).

Finding 6 — Linezolid universally active; TMP-SMX and amikacin >90%; resistance species-specific

"Linezolid was active against all isolates, followed by trimethoprim/sulfamethoxazole (93%) and amikacin (91%)", with resistance linked to defined determinants such as "blaFAR-1 in N. farcinica (resistance to ceftriaxone)" (PMID: 37527397). An independent Indian cohort confirmed "All tested isolates were susceptible to linezolid and 96 % susceptible to amikacin" (PMID: 40112638).

Finding 7 — Diagnosis: microscopy/culture + molecular ID; characteristic CT and MRI findings

Pulmonary CT most commonly shows nodules/masses, ground-glass opacities, consolidation and cavitation — "Multiple or solitary nodules represented the most common CT feature (n = 32, 94.12%), followed by ground-glass opacities (n = 26, 76.47%), patchy consolidations (n = 25, 73.53%), cavitations (n = 18, 52.94%)" — with cavitation associated with immunosuppression ("85% vs 29%, P = 0.005") (PMID: 37185005). Molecular species identification uses "16S rRNA gene sequencing, multilocus sequence analysis (MLSA), matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS), whole-genome sequencing (WGS), and metagenomic next-generation sequencing (mNGS)" (PMID: 42258415).

Finding 8 — Prevention: dose-dependent TMP-SMX prophylaxis; rarely selects resistance

The IPD meta-analysis assessed "its dose-response relationship, its effect on preventing disseminated nocardiosis, and the risk of TMP-SMX resistance in case of breakthrough infection" (PMID: 37865337), reconciling why "low-dose cotrimoxazole prophylaxis was not found to prevent nocardiosis" (PMID: 27090987) — protection is dose-dependent.

Mechanistic Model / Interpretation

ENVIRONMENT (soil, dust, water)
        │  inhalation / traumatic inoculation
        ▼
   ALVEOLAR (or dermal) DEPOSITION
        │  phagocytosis by macrophages
        ▼
   PATHOGEN IMMUNE EVASION ─── katG/sodA (ROS detox)
        │                  ├── mycolic-acid wall (pks13, fadD32, pcaA)
        │                  ├── secreted proteases (tissue damage)
        │                  └── brasilicardin A (local immunosuppression)
        ▼
   INTRACELLULAR SURVIVAL & REPLICATION
        │  (permitted when host cell-mediated immunity is impaired:
        │   corticosteroids, calcineurin inhibitors, low CD4, anti–GM-CSF Ab)
        ▼
   LOCAL SUPPURATIVE / GRANULOMATOUS INFLAMMATION (pneumonia, nodules, cavitation)
        │
        ├──[competent immunity]──► granuloma containment → localized disease
        │
        └──[impaired immunity]───► HEMATOGENOUS DISSEMINATION
                                       │
                                       ▼
                           CNS ► ring-enhancing BRAIN ABSCESS (+ skin, other organs)
                                       │
                                       ▼
                    focal deficit / altered mental status → DEATH (~20–30%)

The unifying theme is a two-hit model: (1) a pathogen equipped to survive inside macrophages and (2) a host whose cell-mediated immunity is pharmacologically or immunologically disabled. Upstream events are environmental exposure and immune-evasion virulence; the pivotal branch point is host immune competence, which determines containment versus dissemination. Therapeutic and preventive levers act at defined points: prophylaxis (block establishment), antibiotics (kill intracellular organisms), surgery (evacuate abscess), and immunosuppression minimization (restore containment).

Evidence Base

Limitations and Knowledge Gaps

1. Template mismatch. This template assumes a heritable/Mendelian disease. For an infectious disease, sections on causal human genes, inheritance, penetrance, germline variant classification, and genetic screening are Not Applicable; molecular content necessarily shifts to pathogen biology.
2. Epidemiology is under-characterized. True population incidence/prevalence is uncertain because nocardiosis is not reportable in most jurisdictions and is under-diagnosed. Regional species-distribution and burden data are inadequate in many settings.
3. Evidence quality. Much of the clinical literature is retrospective case series and single-center cohorts; randomized treatment trials are essentially absent. Treatment durations and regimens are guided by expert consensus, not RCTs.
4. Host-side mechanism is inferred. The requirement for intact cell-mediated immunity is established by clinical association and animal models; direct human mechanistic proof (which T-cell/macrophage pathways fail under specific drugs) is incomplete.
5. In-vitro/in-vivo discordance. Breakthrough disease despite in-vitro susceptibility (PMID: 42135975) shows susceptibility testing imperfectly predicts outcome.
6. Species-level resistance heterogeneity. N. otitidiscaviarum and inter-strain variability complicate empiric therapy (PMID: 42143233).

Proposed Follow-up Experiments / Actions

1. Prospective incidence registry stratified by immunosuppression regimen to define modern population burden and optimal prophylaxis dosing/duration.
2. Randomized/adaptive trial of prophylaxis dosing (single-strength daily vs thrice-weekly) in SOT/HCT to formalize the dose-response signal from PMID: 37865337.
3. WGS-linked antimicrobial-resistance surveillance to build species→resistance prediction rules (extending blaFAR-1/blaAST-1/gyrA/16S-methyltransferase mapping) enabling genotype-guided empiric therapy before phenotypic AST returns.
4. Comparative-effectiveness study of TMP-SMX monotherapy vs combination for disseminated/CNS disease, powered for mortality (current analyses are underpowered, PMID: 36303280).
5. Host-immunity biomarkers (CD4 recovery, anti–GM-CSF autoantibody screening) to risk-stratify and target prophylaxis.
6. Rapid molecular diagnostics (mNGS/tNGS) validation to shorten time-to-species-ID and drainage decisions.
7. Mechanistic dissection of macrophage killing defects under calcineurin inhibitors/corticosteroids using human macrophage-Nocardia infection models to connect the two-hit model to actionable host-directed therapy.

Report compiled from 8 confirmed findings and 59 reviewed papers across 5 investigation iterations. Evidence types span human clinical cohorts/case-control studies, systematic reviews, pathogen genomics, and murine/teleost model-organism studies.